Microbiome Labs, a champion in microbiome-related solutions, inaugurated DigestMate™, a probiotic and 2-in-1 digestive enzyme formula. As observed, the digestive health issues have peaked in the American region, affecting an infinite number of lives, and the demand for innovative solutions has also accelerated. The digestive problem is one of the major conditions affecting the physical and mental health that disturbs the entire daily routine of a person's life. This triggering condition is not yet visible but has a significant largely on the digestive system.
This new formula is a boon for the digestive-challenged population seeking a valuable and effective solution. As per the fetched recent data straight from the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) and the Centers for Disease Control and Prevention (CDC), around 60 to 70 million Americans suffer from digestive diseases every year. These problems have captured 35 million physician visits and around 9 million urgent department visits yearly. This underlines the genuine stress on the quality of life and healthcare systems.
DigestMate™ merges 14 wide-surface, acid-balanced digestive enzymes with a robust, clinically studied fusion of spore-forming probiotic yeast and probiotics. This dual-focused formula contributes to the complete breakdown of fats, complex fibers, proteins and carbohydrates, supporting and bolstering the comprehensive gut hurdle microbial and functional diversity.
Major pressure involves Bacillus subtilis HU58™, Saccharomyces boulardii (CNCM-I-1079) and Bacillus coagulans (SC-208). This helps to balance and contribute to the short-chain fatty acid production and immune responses. This enzyme complex includes protease, lactase, alpha-galactosidase, xylanase, specialised enzymes, glucoamylase, lipase, amylase, and cellulose that will assist in nutrient absorption and help mitigate the occasional digestive discomfort like bloating and gas.
The Med, RD, LD, IFNCP, head of scientific affairs at Microbiome Labs, Alicia Galvin, said, “This is a commendable enzyme formula for the industry and for healthcare practitioners. The merger of digestive enzymes and probiotics is engineered to offer vast digestive support by identifying the gut absorption and nutrient breakdown.”
The DigestMate™ has already been accessible to healthcare practitioners since May 2025 via Microbiome Labs. The lab is a sponsored practitioner network. From 1st December 2025, the DigestMate™ has been added to the Amazon app. The commercialisation stage of this formula has been effectively achieved, and now the company awaits the positive response and expects growth for this fruitful solution to celebrate a milestone ahead.
Mansi Kadam is a market research writer with over 3 years of experience analyzing trends in the healthcare industry. At Towards Healthcare, she covers innovations in medical sector, sustainability initiatives, and the evolving regulatory landscape.
